Risperdal is an antipsychotic medication, used to treat schizophrenia and symptoms of bipolar disorder. It is sometimes prescribed off-label to treat conditions linked to dementia, especially in senior citizens. Other antipsychotic medications include Seroquel (quetiapine) and Zyprexa (olanzapine).
For the study, researchers analyzed data from adults aged 65 and older who were newly prescribed an atypical antipsychotic medication, including risperidone (the generic version of Risperdal). Information was tracked for 90 days following prescription, to identify if patients were treated for a fall or fracture. Researchers found that new prescriptions for atypical antipsychotic medications were associated with a 50 percent increased risk of a serious fall and a 52 percent increased risk of a nonvertebral osteoporotic fracture.
That increased risk was consistent regardless of the specific antipsychotic being prescribed or the dose of medication given.
READ MORE RISPERDAL LEGAL NEWS
According to reports, in 2014, Johnson & Johnson paid more than $1.6 billion in penalties from a settlement announced in November 2013 involving claims of illegal promotion of off-label drug uses. In November 2013, Johnson & Johnson agreed to settle allegations that the company knowingly marketed Risperdal for use in patients with dementia, even though the US Food and Drug Administration had refused to approve it to treat dementia because of an increased risk of stroke in patients using the medication to treat dementia. The Department of Justice also alleged Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, had evidence that Risperdal had an increased risk of diabetes but still marketed the medicine as having no safety concerns.